Modality
Vaccine
MOA
CFTRmod
Target
CD19
Pathway
Autophagy
HNSCC
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
Feb 2023
→ Sep 2031
Phase 1Current
NCT08539684
1,163 pts·HNSCC
2023-02→2031-09·Completed
1,163 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-245.5y awayInterim· HNSCC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
Catalysts
Interim
2031-09-24 · 5.5y away
HNSCC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08539684 | Phase 1 | HNSCC | Completed | 1163 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| Talazasiran | Kymera | NDA/BLA | MET |